ASX Announcements

Jul 2021
Jul 30th, 2021
Quarterly Cashflow and Activities Report
Jul 29th, 2021
Resignation of non-executive director
Jul 28th, 2021
Lynda Cheng appointed as non-executive director
Jul 27th, 2021
Starpharma to present DEP® platform at CRS Annual Meeting
Jul 27th, 2021
VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant
Jul 5th, 2021
TGA infringement notices for alleged advertising
Jul 2nd, 2021
Change in substantial holding

Jun 2021
Jun 24th, 2021
Starpharma to present at Virtual Life Sciences Investor Forum
Jun 21st, 2021
VIRALEZE UK update
Jun 18th, 2021
VIRALEZE SPL7013 virucidal against multiple COVID variants
Jun 11th, 2021
VIRALEZE antiviral nasal spray registered for sale in India
Jun 1st, 2021
VIRALEZE SPL7013 highly active in UK variant of coronavirus

May 2021
May 11th, 2021
VIRALEZE™ partners with Harlequins in the UK
May 6th, 2021
VIRALEZE™ launches in Europe

Apr 2021
Apr 28th, 2021
Shareholder Newsletter
Apr 27th, 2021
Quarterly Cashflow and Activities Report
Apr 9th, 2021
Appendix 2A

Mar 2021
Mar 30th, 2021
VIRALEZE™ now launched by LloydsPharmacy in the UK
Mar 25th, 2021
VIRALEZE™ to be launched with LloydsPharmacy in the UK
Mar 16th, 2021
DEP® HER2-lutetium outperforms in human breast cancer model
Mar 3rd, 2021
SPL7013 active against other pandemic coronaviruses

Feb 2021
Feb 25th, 2021
Interim Report and Half-Year Financial Results
Feb 23rd, 2021
VIRALEZE™ antiviral nasal spray registered in Europe
Feb 12th, 2021
Starpharma signs DEP® ADC Research Agreement with MSD
Feb 9th, 2021
AZD0466 clinical DEP® program global expansion
Feb 3rd, 2021
Change in substantial holding

Jan 2021
Jan 29th, 2021
Quarterly Cashflow and Activities Report
Jan 27th, 2021
Appendix 2A
Jan 18th, 2021
Change in substantial holding
Jan 18th, 2021
Change in substantial holding

Dec 2020
Dec 24th, 2020
Change in substantial holding
Dec 22nd, 2020
VIRALEZE COVID-19 nasal spray study to commence in January
Dec 22nd, 2020
Change in substantial holding
Dec 10th, 2020
VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21

Nov 2020
Nov 24th, 2020
Change in Director's Interest Notice - J Fairley
Nov 24th, 2020
Appendix 3G
Nov 20th, 2020
2020 AGM Results
Nov 20th, 2020
Retirement of non-executive director Richard Hazleton
Nov 20th, 2020
AGM Chairman address and CEO presentation
Nov 19th, 2020
SPL7013 shows potent antiviral activity in RSV
Nov 13th, 2020
Appendix 3G
Nov 4th, 2020
Change in Director's Interest Notice - R Thomas
Nov 4th, 2020
Change in Director's Interest Notice - J Fairley
Nov 4th, 2020
Change in Director's Interest Notice - P Turvey
Nov 4th, 2020
Appendix 2A

Oct 2020
Oct 30th, 2020
Appendix 2A
Oct 30th, 2020
Quarterly Cashflow and Activities Report
Oct 29th, 2020
Completion of Placement and SPP raises $48.9M in total
Oct 21st, 2020
Starpharma receives $5.7M R&D tax incentive refund
Oct 20th, 2020
Shareholder Update October 2020
Oct 19th, 2020
Notice of Annual General Meeting/Proxy Form
Oct 9th, 2020
Change in substantial holding
Oct 8th, 2020
Change in substantial holding
Oct 8th, 2020
Change in substantial holding
Oct 8th, 2020
Change in substantial holding
Oct 7th, 2020
Share Purchase Plan offer document
Oct 6th, 2020
Appendix 2A
Oct 6th, 2020
Cleansing Notice
Oct 5th, 2020
Change in Director's Interest Notice - R Thomas
Oct 5th, 2020
Change in Director's Interest Notice - J Fairley

Sep 2020
Sep 30th, 2020
Investor Presentation
Sep 30th, 2020
Starpharma completes oversubscribed A$45M placement
Sep 30th, 2020
Proposed issue of Securities
Sep 28th, 2020
Trading halt
Sep 25th, 2020
VivaGel® BV secures TGA approval for prevention of BV
Sep 23rd, 2020
2020 Annual General Meeting
Sep 23rd, 2020
Appendix 2A
Sep 18th, 2020
Change in substantial holding
Sep 17th, 2020
Change in substantial holding
Sep 17th, 2020
Starpharma to present at OTCQX Life Sciences Investor Forum
Sep 14th, 2020
SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
Sep 3rd, 2020
Change in substantial holding
Sep 3rd, 2020
Starpharma awarded $1M MRFF funding for COVID-19 spray
Sep 1st, 2020
SPL creates slow release soluble DEP® remdesivir nanoparticle
Sep 1st, 2020
Change in substantial holding

Aug 2020
Aug 27th, 2020
Annual report and full year financial results
Aug 27th, 2020
Appendix 4G - Corporate Governance Statement
Aug 25th, 2020
SPL7013 nasal spray for COVID-19 – development update
Aug 17th, 2020
Starpharma signs new DEP® partnership with Chase Sun

Jul 2020
Jul 30th, 2020
DEP® docetaxel and gemcitabine combination trial commences
Jul 30th, 2020
Quarterly Cashflow and Activities Report
Jul 27th, 2020
AZD0466 trial opens MD Anderson Cancer Center as a site
Jul 9th, 2020
New Australian site opening for DEP® trials

Jun 2020
Jun 29th, 2020
DEP® irinotecan boosts immuno-oncology in colon cancer models
Jun 23rd, 2020
Multiple DEP® products showcased at AACR 2020
Jun 18th, 2020
Starpharma to present at OTCQX Virtual Investor Conference
Jun 17th, 2020
DEP® lutetium effective in human prostate cancer model
Jun 16th, 2020
VivaGel® BV launched in central and eastern European countries
Jun 16th, 2020
Notice of initial substantial holder

May 2020
May 26th, 2020
Notice of initial substantial holder
May 14th, 2020
Shareholder Update May 2020
May 7th, 2020
DEP® irinotecan phase 2 commences after positive phase 1 results
May 5th, 2020
Starpharma presents at Macquarie Australia Conference

Apr 2020
Apr 15th, 2020
SPL7013 shows significant activity against SARS-CoV-2 (coronavirus)
Apr 7th, 2020
Quarterly Cashflow and Activity Report

Mar 2020
Mar 20th, 2020
Appendix 2A
Mar 4th, 2020
Okamoto licenses VivaGel® antiviral condom in Asian countries
Mar 2nd, 2020
Starpharma appoints David McIntyre and Appendix 3X

Feb 2020
Feb 24th, 2020
Interim Report and Half-Year Financial Results
Feb 13th, 2020
VivaGel BV launched in Asia
Feb 12th, 2020
David McIntyre appointed as non-executive director
Feb 11th, 2020
Starpharma receives US$3M milestone from AstraZeneca

Jan 2020
Jan 30th, 2020
Shareholder Update January 2020
Jan 29th, 2020
Quarterly Cashflow Report
Jan 24th, 2020
Appendix 3B

Dec 2019
Dec 30th, 2019
Commencement of phase 1 trial for AZD0466 utilising DEP®
Dec 16th, 2019
Starpharma receives $4.9M R&D tax incentive refund
Dec 10th, 2019
DEP® cabazitaxel progresses to phase 2 on positive results
Dec 4th, 2019
Appendix 3B
Dec 4th, 2019
Change in Director's Interest Notice - J Fairley

Nov 2019
Nov 21st, 2019
AGM Results
Nov 21st, 2019
AGM Chairman’s address and CEO’s presentation
Nov 20th, 2019
VivaGel® condom receives regulatory approval in Europe
Nov 19th, 2019
2019 AGM details
Nov 13th, 2019
UK launch of VivaGel® BV
Nov 12th, 2019
Notice of initial substantial holder

Oct 2019
Oct 31st, 2019
DEP® gemcitabine outperforms Gemzar® in human pancreatic cancer model
Oct 30th, 2019
Quarterly Cashflow Report
Oct 23rd, 2019
Ceasing to be a substantial holder
Oct 23rd, 2019
Change in substantial holding
Oct 18th, 2019
Notice of Annual General Meeting/Proxy Form
Oct 17th, 2019
Appendix 3B
Oct 8th, 2019
Starpharma to present at US Drug Delivery Conference
Oct 1st, 2019
Change in Director's Interest Notice - J Fairley
Oct 1st, 2019
Appendix 3B

Sep 2019
Sep 26th, 2019
FDA Authorisation of First-in-Human Clinical Trial with AstraZeneca’s DEP® product AZD0466
Sep 24th, 2019
AGM Date Notification
Sep 12th, 2019
DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model
Sep 9th, 2019
Change in substantial holding
Sep 3rd, 2019
VivaGel® BV regulatory approvals continue in Asia

Aug 2019
Aug 29th, 2019
Positive results with Targeted DEP® using antibody fragment in human ovarian cancer model
Aug 28th, 2019
Starpharma annual report and full year financial results
Aug 28th, 2019
Appendix 4G – Corporate Governance Statement
Aug 28th, 2019
Promising efficacy signals observed in ongoing DEP® trials, including DEP® cabazitaxel escalation phase
Aug 15th, 2019
First Asian Regulatory Approvals Received for VivaGel® BV
Aug 8th, 2019
Starpharma commences phase 1/2 DEP® irinotecan trial

Jul 2019
Jul 29th, 2019
Appendix 3B
Jul 16th, 2019
Quarterly Cashflow Report
Jul 1st, 2019
Shareholder Update July 2019

Jun 2019
Jun 27th, 2019
VivaGel® BV launched in Europe
Jun 20th, 2019
Starpharma presents at Macquarie Emerging Leaders Forum
Jun 12th, 2019
US patent granted for DEP Bcl2/xL inhibitor conjugates
Jun 4th, 2019
Okamoto launches VivaGel® condom in Japan
Jun 3rd, 2019
Starpharma signs second oncology agreement with AstraZeneca

May 2019
May 29th, 2019
Starpharma presents at UBS Healthcare Conference
May 24th, 2019
DEP irinotecan combination outperforms in refractory human colon cancer model
May 23rd, 2019
Regulatory progress for VivaGel BV in the US
May 7th, 2019
Starpharma to present at US Drug Delivery Conference
May 1st, 2019
Starpharma presents at Macquarie Australia Conference
May 1st, 2019
Notice of Ceasing to be Substantial Holder

Apr 2019
Apr 29th, 2019
Quarterly Cashflow Report
Apr 16th, 2019
First VivaGel BV launch globally in Australia by Aspen
Apr 11th, 2019
Starpharma meets with US FDA to discuss VivaGel® BV
Apr 3rd, 2019
Starpharma Investor Presentation to Goldman Sachs Conference

Mar 2019
Mar 19th, 2019
Appendix 3B
Mar 18th, 2019
Shareholder Update March 2019
Mar 12th, 2019
Starpharma receives $4.0M R&D tax incentive refund

Feb 2019
Feb 27th, 2019
Interim Report and Half-Yearly Financial Results
Feb 8th, 2019
Appendix 3B

Jan 2019
Jan 30th, 2019
Quarterly Cashflow Report
Jan 17th, 2019
Shareholder Update January 2019
Jan 14th, 2019
Notice of initial substantial holder
Jan 7th, 2019
SPL - Response to ASX Aware Letter
Jan 2nd, 2019
VivaGel® condom receives final regulatory approval in Japan